Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.54 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | BLVRB | P30043 | 2/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | PHLPP2 | Q6ZVD8 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL3476110 | 1.00 | MEN1 (0.66) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL29767 | 1.00 | MEN1 (0.66) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL10784910 | 0.94 | MEN1 (0.59) | MEN1KMT2ABLVRBPDE4AKDR | |
| Chrysamine G SCHEMBL15818024 | 0.93 | TDP1 (0.70) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL15201080 | 0.93 | MEN1 (0.79) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL29950230 | 0.91 | MEN1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL27985065 | 0.91 | MEN1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL1614891 | 0.90 | TDP1 (0.57) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL135508 | 0.87 | PLCG1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL428681 | 0.87 | PLCG1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057086-A | Implanted microneedle anastomosis stent, and preparation method and application thereof | 浙江大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RES INST (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240301370-A1 | Ligand Binding Molecules and Uses Thereof | VEGENICS PTY LIMITED (AU) | 2024-09-12 | — | — | US | disclosed |
| US-11866739-B2 | Ligand binding molecules and uses thereof | VEGENICS PTY LIMITED (AU) | 2024-01-09 | — | — | US | disclosed |
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RESEARCH INSTITUTE | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | PTGS1 257/4885PTGS2 313/4885MEN1 4778/4885 |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | PTGS1 257/4885PTGS2 313/4885MEN1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.